A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes

Recent findings suggest that neuronal pathology occurs early in the course of multiple sclerosis and seems to be responsible for accumulation of disability. Nonetheless, the nervous system has an intrinsic potential for repair and compensation in the neuronal component. Disease-modifying drugs such as glatiramer acetate interfere with, and down-regulate, inflammatory pathology and slow neurodegeneration. Moreover, certain regulatory cytokines and neurotrophic factors have the capacity to promote neuronal and axonal repair. Given the importance of neuronal injury in multiple sclerosis and the potential of certain treatments for neuronal repair, it is important to possess adequate and sensitive tools to visualise the pathology in the neuronal compartment. The most promising tools to measure neuronal and axonal damage in multiple sclerosis, as well as neuroprotection and repair, are whole brain volume change for quantification of general brain atrophy, and T1 hypointensity (black holes) and magnetisation transfer ratio for measuring evolution of lesion damage. Other promising techniques, such as diffusion tensor imaging-based fibre tracking and magnetic resonance spectroscopy may allow detailed analyses, but these are still in the experimental stage and are not available for routine clinical practice. Further paraclinical measurements such as optical coherence tomography for the evaluation of the anterior visual pathway may have potential as objective surrogate markers for neurodegeneration in multiple sclerosis.

[1]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[2]  F. Paul,et al.  Perivascular spaces--MRI marker of inflammatory activity in the brain? , 2008, Brain : a journal of neurology.

[3]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[4]  N. Richert Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.

[5]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[6]  Massimo Filippi,et al.  MR Spectroscopy in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[7]  Frederik Barkhof,et al.  Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. , 2005, Radiology.

[8]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[9]  M Filippi,et al.  Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.

[10]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[11]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[12]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[13]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[14]  J S Wolinsky,et al.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. , 2001, Multiple sclerosis.

[15]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[16]  Heinrich Lanfermann,et al.  Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results , 2006, European Radiology.

[17]  M Rovaris,et al.  Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis , 2004, Neurology.

[18]  R. Rudick,et al.  Impact of Disease‐Modifying Therapies on Brain and Spinal Cord Atrophy in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[19]  J. denBoer,et al.  A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging , 1995, Multiple sclerosis.

[20]  A. Thompson,et al.  Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis , 2009, Multiple sclerosis.

[21]  M. Filippi,et al.  250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.

[22]  P. Matthews,et al.  Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.

[23]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[24]  H. Bruhn,et al.  Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.

[25]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[26]  M. Rovaris,et al.  Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. , 2006, Brain : a journal of neurology.

[27]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[28]  F Barkhof,et al.  MR venography of multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[29]  P M Matthews,et al.  Proton MR spectroscopy in multiple sclerosis. , 2000, Neuroimaging clinics of North America.

[30]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[31]  Robert Zivadinov,et al.  The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome , 2008, Journal of Neurology.

[32]  Frederik Barkhof,et al.  MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.

[33]  F. Paul,et al.  Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis , 2009, Neurology.

[34]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[35]  D. Auer,et al.  Spinal Cord Imaging in Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[36]  G. Comi,et al.  Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS , 2008, Journal of Neurology.

[37]  Frauke Zipp,et al.  Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis , 2009, Annals of neurology.

[38]  J. Wuerfel,et al.  CNS‐irrelevant T‐cells enter the brain, cause blood–brain barrier disruption but no glial pathology , 2007, The European journal of neuroscience.

[39]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[40]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[41]  G J Barker,et al.  Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. , 2005, Brain : a journal of neurology.

[42]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[43]  O. Khan,et al.  Long‐Term Study of Brain 1H‐MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long‐Term 1H‐MRS Monitoring in Multiple Sclerosis , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[44]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[45]  Frauke Zipp,et al.  Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. , 2004, Brain : a journal of neurology.

[46]  F. Barkhof,et al.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial , 2008, The Lancet Neurology.

[47]  Richard H. Price,et al.  Black Holes , 1997 .

[48]  C. Kuhl,et al.  Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? , 2006, AJNR. American journal of neuroradiology.

[49]  Massimo Filippi,et al.  Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.